A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease

Cancer Prevention Research

Volumn 6, Issue 12, 2013, Pages 1273-1282

  Disis, Mary L ^a   Gad, Ekram ^a   Herendeen, Daniel R ^a   Phan Lai, Vy ^a   Park, Kyong Hwa ^b   Cecil, Denise L ^a   O'Meara, Megan M ^a   Treuting, Piper M ^a   Lubet, Ronald A ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Korea University   (South Korea)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CANCER VACCINE; DR C GRUBBS; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MULTIANTIGEN POLYPEPTIDE VACCINE; PEPTIDE VACCINE; SESAME SEED OIL; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER SIZE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR INVASION; VACCINE FAILURE;

ADOPTIVE TRANSFER; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; LYMPHOCYTES, TUMOR-INFILTRATING; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; PRECANCEROUS CONDITIONS; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTOR, IGF TYPE 1; T-LYMPHOCYTES; TETRAHYDRONAPHTHALENES; TUMOR CELLS, CULTURED; VACCINES, SUBUNIT;

EID: 84890517532     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0182     Document Type: Article

References (39)

1. Dawood S, Hu R, Homes MD, Collins LC, Schnitt SJ, Connolly J, et al. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat 2011;126:185-92.
2. Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, Ragaz J, et al. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. Cancer Res 2004;64:286-91.
3. Probst-Hensch NM, Steiner JH, Schraml P, Varga Z, Zurrer-Hardi U, Storz M, et al. IGFBP2 and IGFBP3 protein expressions in human breast cancer: association with hormonal factors and obesity. Clin Cancer Res 2010;16:1025-32.
4. So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, et al. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 2008;14:6944-54.
5. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 2000;62:245-52.
6. Park KH, Gad E, Goodell V, Dang Y, Wild T, Higgins D, et al. Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res 2008;68:8400-9.
7. Lai VP, Gad E, Bigdeli L, Dang Y, Stannard C, Disis ML. Antigen-specific T cells cultured in IL-21 demonstrate superior antitumor efficacy secondary to the secretion of IL-17 and TNF-a. J Immunother 2009;32:954.
8. Cecil D, Park KH, Gad E, Higgins D, Childs J, Disis ML. IGF-IR peptide-based vaccines inhibit tumor growth in a murine model of breast cancer. J Immunother 2009;32:954.
9. Kurt RA, Whitaker R, Baher A, Seung S, Urba WJ. Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice. Int J Cancer 2000;87:688-94.
10. Inokuma M, dela Rosa C, Schmitt C, Haaland P, Siebert J, Petry D, et al. Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature. J Immunol 2007;179:2627-33.
11. Saha A, Chatterjee SK. Dendritic cells pulsed with an anti-idiotype antibodymimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice. Cell Immunol 2010;263:9-21.
12. Manjili MH, Wang XY, Chen X, Martin T, Repasky EA, Henderson R, et al. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 2003;171:4054-61.
13. Pupa SM, Invernizzi AM, Forti S, Di Carlo E, Musiani P, Nanni P, et al. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Ther 2001;8:75-9.
14. Knutson KL, Almand B, Dang Y, Disis ML. Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res 2004;64:1146-51.
15. Ramduth D, Day CL, Thobakgale CF, Mkhwanazi NP, de Pierres C, Reddy S, et al. Immunodominant HIV-1 Cd4+ T cell epitopes in chronic untreated clade C HIV-1 infection. PLoS ONE 2009;4:e5013.
16. Nagahama M, Otsuka A, Oda M, Singh RK, Ziora ZM, Imagawa H, et al. Effect of unsaturated bonds in the sn-2 acyl chain of phosphatidylcholine on the membrane-damaging action of Clostridium perfringens alpha-toxin toward liposomes. Biochim Biophys Acta 2007;1768:2940-5.
17. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, et al. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000;19:968-88.
18. Matsuo M, Nagata Y, Sato E, Atanackovic D, Valmori D, Chen YT, et al. IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. Proc Natl Acad Sci U S A 2004;101:14467-72.
19. Li Y, Zhang Y, Hill J, Kim HT, Shen Q, Bissonnette RP, et al. The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br J Cancer 2008;98:1380-8.
20. Strecker TE, Shen Q, Zhang Y, Hill JL, Li Y, Wang C, et al. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst 2009;101:107-13.
21. Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010;102:627-37.
22. Roses RE, Paulson EC, Sharma A, Schueller JE, Nisenbaum H, Weinstein S, et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2009;18:1386-9.
23. Nofech-Mozes S, Spayne J, Rakovitch E, Kahn HJ, Seth A, Pignol JP, et al. Biological markers predictive of invasive recurrence in DCIS. Clin Med Oncol 2008;2:7-18.
24. Czerniecki BJ, Roses RE, Koski GK. Development of vaccines for high-risk ductal carcinoma in situ of the breast. Cancer Res 2007;67:6531-4.
25. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20:2624-32.
26. Kleinberg DL, Wood TL, Furth PA, Lee AV. Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 2009;30:51-74.
27. Busund LT, Richardsen E, Busund R, Ukkonen T, Bjornsen T, Busch C, et al. Signi ficant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol 2005;58:361-6.
28. Tamimi RM, Colditz GA, Wang Y, Collins LC, Hu R, Rosner B, et al. Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. Breast Cancer Res Treat 2011;128:243-50.
29. Furstenau DK, Mitra N, Wan F, Lewis R, Feldman MD, Fraker DL, et al. Ras-related protein 1 and the insulin-like growth factor type I receptor are associated with risk of progression in patients diagnosed with carcinoma in situ. Breast Cancer Res Treat 2011;129:361-72.
30. Bhargava R, Beriwal S, McManus K, Dabbs DJ. Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma. Appl Immunohistochem Mol Morphol 2011;19:218-25.
31. Zhou F. Molecular mechanisms of viral immune evasion proteins to inhibit MHC class I antigen processing and presentation. Int Rev Immunol 2009;28:376-93.
32. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A 2012;109:2802-7.
33. Pedroza-Gonzalez A, Xu K, Wu TC, Aspord C, Tindle S, Marches F, et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med 2011;208:479-90.
34. Hoogerbrugge N, Bult P, de Widt-Levert LM, Beex LV, Kiemeney LA, Ligtenberg MJ, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 2003;21:41-5.
35. Leunen K, Drijkoningen M, Neven P, Christiaens MR, Van Ongeval C, Legius E, et al. Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us? Breast Cancer Res Treat 2008;107:79-86.
36. Bhathal PS, Brown RW, Lesueur GC, Russell IS. Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. Br J Cancer 1985;51:271-8.
37. Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood 2002;100:1399-403.
38. Rasooly R, Schuster GU, Gregg JP, Xiao JH, Chandraratna RA, Stephensen CB. Retinoid x receptor agonists increase bcl2a1 expression and decrease apoptosis of naive T lymphocytes. J Immunol 2005;175:7916-29.
39. Lu B, Finn OJ. T-cell death and cancer immune tolerance. Cell Death Differ 2008;15:70-9.